样式: 排序: IF: - GO 导出 标记为已读
-
Reply on « Commentary on Giant cell arteritis associated with scalp, tongue or lip necrosis in a French study.” Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-03-13 Ferida Chehem Daoud Chehem, Olivier Espitia, Christian Agard
-
Clinical and imaging outcomes of different phenotypes of axial spondyloarthritis: 5-year analysis of the DESIR cohort Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-03-02 Alexandre Sepriano, Sofia Ramiro, Désirée van der Heijde, Anna Moltó, Cécile Gaujoux-Viala, Maxime Dougados, Robert Landewé
To compare the long-term outcomes of three phenotypes of axial SpA (axSpA). Patients with a clinical diagnosis of axSpA from the DESIR cohort were grouped into three phenotypes at baseline: ‘Pure axSpA’ (‘Axial’), ‘axSpA with peripheral signs’ (‘IBP+Peripheral’) and ‘axSpA at risk’ (‘At risk’) by latent class analysis. Clinical and imaging data were collected up to 5 years. Clinical outcomes, measured
-
Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-03-01 Seher Sener, Veysel Cam, Seza Ozen, Ezgi Deniz Batu
[Display omitted]
-
Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-03-01 Gregory C McDermott, Michael DiIorio, Yumeko Kawano, Mary Jeffway, Megan MacVicar, Kumar Dahal, Su-Jin Moon, Thany Seyok, Jonathan Coblyn, Elena Massarotti, Michael E Weinblatt, Dana Weisenfeld, Katherine P Liao
Switching biologic and targeted synthetic DMARD (b/tsDMARD) medications occurs commonly in RA patients, however data are limited on the reasons for these changes. The objective of the study was to identify and categorize reasons for b/tsDMARD switching and investigate characteristics associated with treatment refractory RA. In a multi-hospital RA electronic health record (EHR) cohort, we identified
-
Defining domains: developing consensus-based definitions for foundational domains in OMERACT core outcome sets Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-29 Lara J. Maxwell, Caitlin Jones, Clifton O Bingham, Maarten Boers, Annelies Boonen, Ernest Choy, Robin Christensen, Philip G. Conaghan, Maria Antonietta D'Agostino, Andrea S. Doria, Shawna Grosskleg, Catherine L. Hill, Catherine Hofstetter, Ben Horgan, Féline Kroon, Ying Ying Leung, Sarah Mackie, Alexa Meara, Beverley J Shea, Lee S Simon, Zahi Touma, Peter Tugwell, George A Wells, Dorcas E Beaton
To develop a set of detailed definitions for foundational domains commonly used in OMERACT (Outcome Measures in Rheumatology) core domain sets. We identified candidate domain definitions from prior OMERACT publications and websites and publications of major organizations involved in outcomes research for six domains commonly used in OMERACT Core Domain Sets: pain intensity, pain interference, physical
-
Embracing unity at OMERACT: Valuing equity, promoting diversity, fostering inclusivity Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-29 Lara J Maxwell, Grace C Wright, Grayson Schultz, Shawna Grosskleg, Jennifer L Barton, Willemina Campbell, Francis Guillemin, Catherine Hofstetter, Beverley J Shea, Lee S Simon, Adewale Adebajo, Cheryl Barnabe, Niti Goel, Patricia Hurley, Elena Nikiphorou, Jennifer Petkovic, Peter Tugwell
To increase awareness and understanding of the principles of Equity, Diversity, and Inclusivity (EDI) within Outcome Measures in Rheumatology's (OMERACT) members. For this, we aimed to obtain ideas on how to promote and foster these principles within the organization and determine the diversity of the current membership in order to focus future efforts. We held a plenary workshop session at OMERACT
-
Imaging to predict early relapses after treatment discontinuation in patients with large vessel giant cell arteritis – A cohort study Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-28 Andrea K. Hemmig, Christof Rottenburger, Luan Baruti, Noemi Mensch, Markus Aschwanden, Diego Kyburz, Maurice Pradella, Daniel Staub, Mihaela Stegert, Christoph T. Berger, Stephan Imfeld, Gregor Sommer, Thomas Daikeler
To investigate the value of [F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI) in predicting relapse after treatment discontinuation in patients with large-vessel giant cell arteritis (LV-GCA). This study included patients with LV-GCA whose treatment was discontinued between 2018 and 2023. All patients underwent PET/CT and/or MRI at
-
Commentary on giant cell arteritis associated with scalp, tongue or lip necrosis in a French study Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-23 F, e, n, g, , W, a, n, g
-
A multi-national survey to identify clinicians’ perspectives concerning Proton Pump inhibitors in patients with systemic sclerosis Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-23 Giulia Bandini, Alessia Alunno, Filipe Oliveira Pinheiro, Corrado Campochiaro, Ilaria Galetti, Pietro Matucci Cerinic, Barbara Ruaro, Alberto Moggi Pignone, Silvia Bellando Randone, Lorenzo Dagna, Marco Matucci Cerinic, Zsuzsanna H McMahan, Michael Hughes
Proton Pump Inhibitors (PPIs) are widely used in SSc for gastroesophageal reflux disease (GERD). However, there is little evidence to support their empirical use and long-term safety has been questioned. Our objective was to better describe clinicians’ attitudes toward PPIs prescription and use in SSc patients. Clinicians involved in the care of SSc patients were invited through international physician
-
Navigating the path of progress: The OMERACT 2023 emerging leaders program Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-21 T Mark Campbell, Stephanie Finzel, Heidi Siddle, Robin Christensen, Sabrina Mai Nielsen, Aurelie Najm, Tarimobo M. Otobo, Ilfita Sahbudin, Premarani Sinnathurai, Kathryn S. Stok, Zahi Touma, Karine Toupin April, Shawna Grosskleg, Peter Tugwell, Bethan Richards
The Outcome Measures in Rheumatology Clinical Trials (OMERACT) Emerging Leaders Program (ELP) aims to cultivate a cohort of skilled leaders within the OMERACT community empowering them with expertise and knowledge to help shape and steer the organization into the future. This publication highlights the significance of the ELP in driving leadership excellence, its impact on OMERACT's evolution, and
-
The value of musculoskeletal ultrasound in predicting gout flares in index joints: a prospective cohort study of people with gout starting urate-lowering therapy Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-18 Lin Han, Runze Li, Nicola Dalbeth, Mingdi Liu, Qing Yu, Caiyun Jiang, Chunping Ning, Zhen Liu, Yuwei He, Maichao Li, Xiaomei Xue, Fenghao Jia, Zhaotong Jia, Wenyan Sun, Hui Zhang, Jie Lu, Can Wang, Changgui Li
[Display omitted]
-
OMERACT validation of a deep learning algorithm for automated absolute quantification of knee joint effusion versus manual semi-quantitative assessment. Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-17 Banafshe Felfeliyan, Stephanie Wichuk, Abhilash Rakkunedeth, Robert Lambert, Walter P. Maksymowych, Jacob Jaremko
To begin evaluating deep learning (DL)-automated quantification of knee joint effusion-synovitis via the OMERACT filter. A DL algorithm previously trained on Osteoarthritis Initiative (OAI) knee MRI automatically quantified effusion volume in MRI of 53 OAI subjects, which were also scored semi-quantitatively via KIMRISS and MOAKS by 2-6 readers. DL-measured knee effusion correlated significantly with
-
Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: A population-based cohort study Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-15 Huan Meng, Steven H. Lam, Ho So, Lai-Shan Tam
To evaluate the incidence and risk factors of major adverse cardiovascular events (MACE) in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients. A population-based retrospective cohort of RA and PsA patients was identified in a citywide database. All patients recruited from Jan 2006 to Dec 2015 were followed until the end of 2018. The outcome was the occurrence of a first MACE. Covariates
-
Maternal and fetal outcomes of pregnancy in women with primary systemic vasculitis: A single-center cohort study of 20 patients and 30 pregnancies Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-14 Sara Beça, Marco A Alba, José Hernández-Rodríguez, Georgina Espígol-Frigolé, Sergio Prieto-González, María C Cid, Núria Baños, Gerard Espinosa
To analyze pregnancy outcomes of patients with primary systemic vasculitis followed in a third-level referral center. Retrospective cohort study of all pregnant women with systemic vasculitis followed between 2009 and 2022 at the High-Risk Pregnancy Clinic of the Department of Systemic Autoimmune Diseases of the Hospital Clínic, Barcelona. Twenty women with primary vasculitis were identified, with
-
Strategies to promote implementation of core outcomes for medication adherence trials in Rheumatology: A report from the OMERACT-Adherence Group Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-13 Aria Mohammadi Kordkheili, Charlotte Bekker, Alison M Hoens, Marieke Voshaar, Willemina Campbell, Loreto Carmona, Maarten de Wit, Lyn March, Sabrina Mai Nielsen, Beverley J Shea, Karine Toupin-April, Peter Tugwell, Kathleen Tymms, Ayano Kelly
To identify barriers, facilitators, and strategies for future implementation of the OMERACT-Adherence Core Outcome Set (COS) in medication adherence trials for Rheumatic conditions. Preliminary Delphi survey findings were discussed at OMERACT 2023, utilising the Consolidated Framework for Implementation Research 2 to identify implementation barriers, facilitators, and solutions. Implementation strategies
-
Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-12 Ludovic Trefond, Raphael Lhote, Alexis Mathian, Marc Pineton de Chambrun, Micheline Pha, Miguel Hie, Makoto Miyara, Matthias Papo, Quentin Moyon, Dov Taieb, Sonia Saade, Thouraya Ben Salem, Julien Haroche, François Chasset, Fleur Cohen Aubart, Noël Zahr, Zahir Amoura
Long-term hydroxychloroquine (HCQ) or chloroquine (CQ) intake causes retinal toxicity in 0.3–8% of patients with rheumatic diseases. Numerous risk factors have been described, eg, daily dose by weight, treatment duration, chronic kidney disease, concurrent tamoxifen therapy and pre-existing retinal or macular disease. However, those factors cannot explain the entire risk of developing antimalarial
-
Response to comments on “Male rheumatoid arthritis patients at substantially higher risk for cardiovascular mortality in comparison to women” by Koet. Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-09 Reinder Raadsen, Romy Hansildaar, Arno W.R. van Kuijk, Michael T. Nurmohamed
-
The Differential role of SSa/SSb and Ro52 antibodies in defining clinical phenotypes in Idiopathic Inflammatory Myopathies Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-08 Ana Valle, Sonali Narain, Maria-Louise Barilla-Labarca, Galina Marder
In idiopathic inflammatory myopathies, anti-SSa/SSb and anti-Ro52 are associated with interstitial lung disease (ILD), yet few studies have compared their prognostic utility. Our study analyzes clinical phenotypes associated with anti-SSa/SSb and anti-Ro52 positivity in IIM and their association with ILD. We performed a retrospective analysis of IIM patients >18-years-old, seen at Northwell Myositis
-
Relationship between spinal structural damage and sagittal balance in axial spondyloarthritis: Is the thoracic spine the starting point? Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-07 Thauana L Oliveira, Flávio D Silva, Alípio G O Filho, Marcelo A C Nico, Artur R C Fernandes, Sofia Ramiro, Marcelo M Pinheiro
To assess the relationship between spinal structural damage, sagittal balance parameters and spine curvatures in patients with axial spondyloarthritis (axSpA). In this cross-sectional study, the pelvic and sagittal balance parameters were obtained through EOS® (Biospace, Paris, France). Patients were divided into three groups according to the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS)
-
Eosinophilic giant cell arteritis: A different subset of disease? Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-05 Luigi Boiardi, Chiara Marvisi, Pierluigi Macchioni, Alberto Cavazza, Stefania Croci, Giulia Besutti, Lucia Spaggiari, Paolo Giorgi Rossi, Luca Cimino, Nicolò Pipitone, Caterina Ricordi, Francesco Muratore, Carlo Salvarani
To describe the clinical findings, response to therapy and course of patients with transmural eosinophilic infiltration at temporal artery biopsy (TAB). The study consisted of a retrospective cohort of 254 consecutive GCA patients with evidence of transmural inflammation at TAB seen at the Santa Maria Nuova Hospital over a 28-year period. The findings of the 22 patients with eosinophilic infiltration
-
Clinical characteristics of adolescent-onset gout in Chinese: A hospital-based cross-sectional study Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-05 Yushuang Li, Tony R. Merriman, Haibing Chen, Qingguo Lv, Yinkun Yan, Xinmiao Xu, Aichang Ji, Zan Cheng, Xiaxia Wang, Di Lu, Lin Han, Lingling Cui, Can Wang, Wenyan Sun, Changgui Li, Jie Lu
-
Standardization of Interstitial Lung Disease Assessment by Ultrasound: Results from a Delphi Process and Web-reliability exercise by the OMERACT Ultrasound Working Group Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-05 Delle Sedie Andrea, Terslev Lene, A.W. Bruyn George, Cazenave Tomas, Chrysidis Stavros, Diaz Mario, Di Carlo Marco, Frigato Marilena, Gargani Luna, Gutierrez Marwin, Hocevar Alojzija, Iagnocco Annamaria, Juche Aaron, Keen Helen, Mandl Peter, Naredo Esperanza, Mortada Mohamed, Pineda Carlos, Karalilova Rositsa, Porta Francesco, Ravagnani Viviana, Scirè Carlo, Serban Teodora, Smith Kate, S Stoenoiu Maria
Over the last years ultrasound has shown to be an important tool for evaluating lung involvement, including interstitial lung disease (ILD) a potentially severe systemic involvement in many rheumatic and musculoskeletal diseases (RMD). Despite the potential sensitivity of the technique the actual use is hampered by the lack of consensual definitions of elementary lesions to be assessed and of the scanning
-
Qualitative evaluation of connective tissue disease with cytomegalovirus infection: A meta-analysis of case reports Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-05 Ruiting Deng, Gaodi Yuan, Yiman Ye, Wenxuan Luo, Jiaxun Zhong, Haolan Wang, Xin Wei, Xiongyan Luo, Anji Xiong
: The primary therapies for connective tissue disease include glucocorticoids and immunosuppressants. However, their prolonged usage can precipitate opportunistic infections, such as cytomegalovirus infection. When managing connective tissue disease complicated by cytomegalovirus infection, judicious selection of treatment modalities is crucial. This involves assessing the necessity for antiviral therapy
-
Evolving and evaluating the OMERACT fellows program: insights and implications from OMERACT 2023 fellows Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-04 Lara S. Chapman, Ayano Kelly, Erin Balay-Dustrude, Charlotte Bekker, Dorthe B. Berthelsen, Nilasha Ghosh, Rachael A. Gordon, Romi Haas, Caitlin Jones, Andre Luquini, Max Weinbrecht-Mischkewitz, Tim Pickles, Didem Saygin, Wils Nielsen, Casper Webers, Shawna Grosskleg, Peter Tugwell, Maria Antonietta D'Agostino, Francis Guillemin, Lyn March
To describe the evolution of the OMERACT Fellows Program (OM FP) and to evaluate the innovative changes implemented in the 2023 program. The OM FP, the first of its kind in global rheumatology, was developed in 2000 to mentor early career researchers in methods and processes for reaching evidence-driven consensus for outcome measures in clinical studies. The OM FP has evolved through continuing iterations
-
Response to “Do not ignore another risk factor of invasive fungal infections in patients with connective tissue disease” Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-29 Wenxuan Luo, Huawei Tu, Anji Xiong
Abstract not available
-
The OMERACT whole-body MRI scoring system for inflammation in peripheral joints and entheses (WIPE) in spondyloarthritis - reference image atlas for the knee region Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-03 Mikkel Østergaard, Marie Wetterslev, Anna EF Hadsbjerg, Walter P Maksymowych, Iris Eshed, Lennart Jans, Yasser Emad, Susanne J Pedersen, Maria S Stoenoiu, Paul Bird, Violaine Foltz, Ashish J Mathew, Joel Paschke, Philippe Carron, Gabriele De Marco, Helena Marzo-Ortega, Signe Møller-Bisgaard, Philip G Conaghan, Robert GW Lambert
To develop a reference image atlas for the Outcome Measures in Rheumatology whole-body MRI scoring system for inflammation in peripheral joints and entheses (OMERACT MRI-WIPE) of the knee region. Image examples of each pathology, location and grade, were collected and discussed at web-based, interactive meetings within the OMERACT MRI in Arthritis Working Group. Subsequently, reference images were
-
Effects of neuromuscular control and strengthening exercises on MRI-measured thigh tissue composition and muscle properties in people with knee osteoarthritis – an exploratory secondary analysis from a randomized controlled trial Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-03 Pætur M. Holm, Anne Dorte Blankholm, Jakob L. Nielsen, Thomas Bandholm, Wolfgang Wirth, Anna Wisser, Jana Kemnitz, Felix Eckstein, Henrik M. Schrøder, Mathias Wernbom, Søren T. Skou
To investigate the effects of adding strength training to neuromuscular control exercises on thigh tissue composition and muscle properties in people with radiographic-symptomatic knee osteoarthritis (KOA). In this exploratory secondary analysis of a randomized controlled trial, using a complete-case approach, participants performed 12 weeks of twice-weekly neuromuscular control exercise and patient
-
Hip and pelvis region MRI reference image atlas for scoring inflammation in peripheral joints and entheses according to the OMERACT-MRI WIPE scoring system in patients with spondyloarthritis Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-02 Mikkel Østergaard, Robert GW Lambert, Anna EF Hadsbjerg, Iris Eshed, Walter P Maksymowych, Ashish J Mathew, Lennart Jans, Susanne J Pedersen, Philippe Carron, Yasser Emad, Gabriele De Marco, Paul Bird, Maria S Stoenoiu, Violaine Foltz, Joel Paschke, Helena Marzo-Ortega, Signe Møller-Bisgaard, Philip G Conaghan, Marie Wetterslev
To develop a reference image atlas for scoring the hip/pelvis region according to the OMERACT whole-body MRI scoring system for inflammation in peripheral joints and entheses (MRI-WIPE). We collected image examples of each pathology, location and grade, discussed them at web-based, interactive meetings and, finally, selected reference images by consensus. Reference images for each grade and location
-
Patients’ perspectives on systemic sclerosis-related Raynaud's phenomenon in the feet: A qualitative study from the OMERACT Foot and Ankle Working Group Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-02 Lara S. Chapman, Begonya Alcacer-Pitarch, John D. Pauling, Caroline A. Flurey, Anthony C. Redmond, Pamela Richards, Ariane L. Herrick, Peter A. Merkel, Susanna Proudman, Hylton B. Menz, Philip S. Helliwell, Marian T. Hannan, Robyn T. Domsic, Lesley A. Saketkoo, Beverley Shea, Heidi J. Siddle
-
Effect modification of cancer on the association between dysphagia and mortality in early idiopathic inflammatory myopathies Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-02 Valérie Leclair, Antonella Notarnicola, Olga Kryštůfková, Herman Mann, Helena Andersson, Louise Pyndt Diederichsen, Jiri Vencovský, Marie Holmqvist, Ingrid E. Lundberg, Russell J. Steele, Marie Hudson
The interplay between dysphagia, cancer, and mortality in idiopathic inflammatory myopathies (IIM) has not been carefully studied. The aim of this study was to investigate possible effect modification of cancer on the association between dysphagia and mortality in early IIM. A multi-center cohort of 230 adult IIM patients with dysphagia assessment within 6 months of disease onset was assembled. Crude
-
Assessing domain match and feasibility of candidate instruments matching with OMERACT endorsed domains to measure flare in knee and hip osteoarthritis Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-01 F. Queiroga, S.M. Cembalo, J. Epstein, L. Maxwell, T. Buttel, C. Copenhaver, M. Cross, D. Hunter, L. King, L. Callahan, L. March, D.E. Beaton, F. Guillemin
To evaluate the domain match (truth) and feasibility of candidate instruments assessing flare in knee and hip osteoarthritis (OA) according to the identified domains. From a literature review (575 papers), instruments were selected and evaluated using the truth and feasibility elements of the OMERACT Filter 2.2. These were evaluated by 26 experts, including patients, in two Delphi survey rounds. The
-
Male rheumatoid arthritis patients at substantially higher risk for cardiovascular mortality in comparison to women Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-02-01 Lukas B.M. Koet
Abstract not available
-
Identification of outcome domains in primary Sjögren's disease: a scoping review by the OMERACT Sjögren disease working group Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-30 Yann Nguyen, Maxime Beydon, Nathan Foulquier, Rachael Gordon, Coralie Bouillot, Katherine M Hammitt, Simon J Bowman, Xavier Mariette, Sara S McCoy, Divi Cornec, Raphaèle Seror
Objectives Sjögren's disease (SjD) is a heterogenous disease with a wide range of manifestations, ranging from symptoms of dryness, fatigue, and pain, to systemic involvement. Considerable advances have been made to evaluate systemic activity or patient-reported outcomes, but most of the instruments were not able to assess all domains of this multifaceted disease. The aim of this scoping review was
-
Do not ignore another risk factor of invasive fungal infections in patients with connective tissue disease Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-29 Diao Yu, Jinlin Liu, Yanxia Chen
Abstract not available
-
Come rain or shine: is weather a risk factor for musculoskeletal pain? A systematic review with meta-analysis of case-crossover studies Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-28 Manuela L Ferreira, David J Hunter, Allan Fu, Shahreen Raihana, Donna Urquhart, Paulo H Ferreira
Objectives The weather is frequently blamed for changes in health behaviour and adverse health events. However, despite the frequency with which this phenomenon is endorsed, past research is largely conflicting. This meta-analysis has reviewed, appraised and summarised case-crossover studies assessing the transient risk of musculoskeletal symptoms associated with weather parameters (e.g. temperature
-
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-26 Sara Nysom Christiansen, Simon Horskjær Rasmussen, Marion Pons, Brigitte Michelsen, Bente Glintborg, Bjorn Gudbjornsson, Gerdur Grondal, Jiri Vencovsky, Anne Gitte Loft, Ziga Rotar, Katja Perdan Pirkmajer, Michael J. Nissen, Jana Baranová, Gary J. Macfarlane, Gareth T. Jones, Florenzo Iannone, Roberto Caporali, Karin Laas, Sigrid Vorobjov, Daniela Di Giuseppe, Lykke Midtbøll Ørnbjerg
Objectives In patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) initiating secukinumab, we aimed to assess and compare the proportion of patients achieving 6-, 12- and 24-month patient-reported outcomes (PRO) remission and the 24-month retention rates. Patients and methods Patients with axSpA or PsA from 16 European registries, who initiated secukinumab in routine care were
-
Risk of cardiovascular comorbidities before and after the onset of rheumatic diseases Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-26 Hanna-Kaisa Aaramaa, Nina Mars, Mika Helminen, Anne M Kerola, Antti Palomäki, Kari K Eklund, Javier Gracia-Tabuenca, Juha Sinisalo, , Pia Isomäki
-
The management of cardiovascular risk in psoriatic disease: a bridge over troubled water Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-24 Alessia Alunno, Francesco Carubbi, Javier-Rodríguez Carrio, Laure Gossec, Siobhán Donohoe, Claudio Ferri
Evidence that psoriatic disease is burdened by an excess cardiovascular (CV) risk has accrued, however many questions remain unanswered. Although an interplay between traditional risk factors inflammation, disease activity and pharmacological therapies, as observed in rheumatoid arthritis (RA), may account for this increased risk, metabolic comorbidities rather than inflammation seem to have a leading
-
Proximal weakness and creatine kinase elevation in systemic sclerosis: Clinical correlates, prognosis and functional implications Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-24 Jessica L. Fairley, Dylan Hansen, Jessica Day, Susanna Proudman, Joanne Sahhar, Gene-Siew Ngian, Jenny Walker, Lauren V. Host, Kathleen Morrisroe, Wendy Stevens, Laura Ross, Mandana Nikpour
-
The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-23 Rachael A. Gordon, Yann Nguyen, Nathan Foulquier, Maxime Beydon, Tamer A Gheita, Raouf Hajji, Ilfita Sahbudin, Alberta Hoi, Wan-Fai Ng, Jose Alexandre Mendonça, Daniel J Wallace, Beverley Shea, George AW Bruyn, Susan M Goodman, Benjamin A Fisher, Chiara Baldini, Karina D Torralba, Hendrika Bootsma, Esen K Akpek, Sezen Karakus, Raphaele Seror
Sjögren's disease (SjD) is a systemic autoimmune exocrinopathy with key features of dryness, pain, and fatigue. SjD can affect any organ system with a variety of presentations across individuals. This heterogeneity is one of the major barriers for developing effective disease modifying treatments. Defining core disease domains comprising both specific clinical features and incorporating the patient
-
PROMIS-29 in rheumatoid arthritis patients who screen positive or negative for fibromyalgia on MDHAQ FAST4 (fibromyalgia assessment screening tool) or 2011 fibromyalgia criteria Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-18 Kathryn A. Gibson, Robert M. Kaplan, Theodore Pincus, Tengfei Li, George Luta
Background PROMIS-29 T-scores query health-related quality of life (HRQL) in 7 domains, physical function, pain, fatigue, anxiety, depression, sleep quality, and social participation, to establish population norms. An MDHAQ (multidimensional health assessment questionnaire) scores these 7 domains and includes medical information such as a FAST4 (fibromyalgia assessment screening tool) index. We analyzed
-
Author Reply to Letter to the Editor Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-17 Yeo-Jin Song, Soo-Kyung Cho, Jeong-Yeon Kim, Seung-Hun You, Hyoungyoung Kim, Sun-Young Jung, Yoon-Kyoung Sung
Abstract not available
-
Patient global assessment and inflammatory markers in patients with idiopathic inflammatory myopathies – A longitudinal study Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-14 Karin Lodin, Fabricio Espinosa-Ortega, Maryam Dastmalchi, Jiri Vencovsky, Helena Andersson, Hector Chinoy, James B. Lilleker, Samuel Katsuyuki Shinjo, Britta Maurer, Zoltan Griger, Angela Ceribelli, Jiram Torres-Ruiz, Monica Vasquez-Del Mercado, Dag Leonard, Helene Alexanderson, Ingrid E. Lundberg
Aim To explore if patient global assessment (PGA) is associated with inflammation over time and if associations are explained by other measures of disease activity and function in patients with idiopathic inflammatory myopathies (IIM). Methods PGA and systemic inflammatory markers prospectively collected over five years were retrieved from the International MyoNet registry for 1200 patients with IIM
-
Precision management in SAPHO syndrome: Stratified care based on various skin manifestations Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-15 Xiao-Jun Shi, Luying Wang, Yi-Hang Ding, Xiu-Juan Hou, Chen Li
Abstract not available
-
The autoimmune rheumatological presentation of Common Variable Immunodeficiency Disorders with an overview of genetic testing Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-17 Rohan Ameratunga, See-Tarn Woon, Euphemia Leung, Edward Lea, Lydia Chan, James Mehrtens, Hilary Longhurst, Richard Steele, Klaus Lehnert, Karen Lindsay
Primary immunodeficiency Disorders (PIDS) are rare, mostly monogenetic conditions which can present to a number of specialties. Although infections predominate in most PIDs, some individuals can manifest autoimmune or inflammatory sequelae as their initial clinical presentation. Identifying patients with PIDs can be challenging, as some can present later in life. This is often seen in patients with
-
Autoimmune rheumatic disease in Australian Aboriginal and Torres Strait Islander Peoples: What do we know? Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-14 Laura E Eades, Jason Sines, Alberta Y Hoi, Ruaidhri Liddle, Rangi Kandane-Rathnayake, Eric F Morand, Stephen Brady, Maureen Rischmueller, Fabien B Vincent
Autoimmune rheumatic disease (AIRD) is a collective term, which comprises a group of multisystem inflammatory autoimmune diseases, including connective tissue disease, chronic inflammatory arthritis, sarcoidosis and systemic vasculitis. Some AIRD are prevalent in the general population, and all can cause significant morbidity and reduced quality of life, with some increasing the risk of premature mortality
-
Acknowledgement of Referees Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-14 Giovanni Adami, Graciela Alarcon, Daniel Albert, Kelli Allen, Martin Aringer, Elizabeth V. Arkema, Hossam M. Ashour, Fabiola Atzeni, Gizem Ayan, Alan Baer, Joshua Baker, Claire Barber, Wilson Bautista-Molano, Sara Beça, Brock Beamer, Sytske Anne Bergstra, Bonnie Bermas, Emre Bilgin, Maarten Boers, Marcy Bolster, Wen Zhang
Abstract not available
-
Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-15 Simon Décary, Maarten de Wit, Florian Naye, Jennifer L. Barton, Liana Fraenkel, Linda C. Li, Peter Brooks, Dawn Stacey, Lara J. Maxwell, Willemina Campbell, Cathie Hofstetter, Marieke Voshaar, Alexa Meara, Robin Christensen, Annelies Boonen, Maria E. Suarez-Almazor, Tanya Meade, Lyn March, Janet Elizabeth Jull, Rieke Alten, Karine Toupin-April
Objective To gain consensus on the definitions and descriptions of the domains of the Outcome Measures in Rheumatology (OMERACT) core domain set for rheumatology trials evaluating shared decision making (SDM) interventions. Methods Following the OMERACT Handbook methods, our Working Group (WG), comprised of 90 members, including 17 patient research partners (PRPs) and 73 clinicians and researchers
-
Multiple morbidities are associated with serious infections in patients with rheumatoid arthritis Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-15 Bradly A. Kimbrough, Cynthia S. Crowson, Ryan J. Lennon, John M Davis, Anja Strangfeld, Elena Myasoedova
Objective To assess the association between a comprehensive list of morbidities and serious infection (SI) in patients with rheumatoid arthritis (RA). Methods This study evaluated SI risk associated with 55 comorbidities using a population-based inception cohort including all adult patients with incident RA from 1999 through 2014 with follow up through 2021. Morbidities and SI were ascertained using
-
Associations of galectin-3 levels with measures of vascular disease in patients with rheumatoid arthritis Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-15 Amanda Nussdorf, Elizabeth Park, Isabelle Amigues, Laura Geraldino-Pardilla, Sabahat Bokhari, Jon T Giles, Joan M Bathon
Objectives Galectin-3 is a beta-galactoside-binding lectin and is a marker of cardiovascular disease (CVD) in the general population. It may also play a role in joint inflammation. We asked whether serum galectin-3 is a useful marker of subclinical vascular disease in patients with rheumatoid arthritis (RA). Methods RA patients without clinical CVD underwent assessment of coronary artery calcium (CAC)
-
Moving urate-lowering therapy in gout beyond guideline recommendations Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-10 Lisa K Stamp, Nicola Dalbeth
The 'treat-to target serum urate strategy' when using urate-lowering therapy has been recommended by most specialist rheumatology societies for many years. An alternative “treat-to-avoid-symptoms” in gout has been suggested, albeit without a clear definition of what this means and how it might be implemented in clinical trials or clinical practice. This has hampered efforts to design clinical trials
-
OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-14 Wils Nielsen, Vibeke Strand, Lee S. Simon, Ioannis Parodis, Alfred H.J. Kim, Maya Desai, Yvonne Enman, Daniel Wallace, Yashaar Chaichian, Sandra Navarra, Cynthia Aranow, Meggan MacKay, Kimberly Trotter, Oshrat E. Tayer-Shifman, Ali Duarte-Garcia, Lai Shan Tam, Manuel F. Ugarte-Gil, Guillermo J. PonsEstel, John A. Reynolds, Mandana Nikpour, Zahi Touma
Background The Outcome Measures in Rheumatology (OMERACT) Systemic Lupus Erythematosus (SLE) Working Group held a Special Interest Group (SIG) at the OMERACT 2023 conference in Colorado Springs where SLE collaborators reviewed domain sub-themes generated through qualitative research and literature review. Objective The objective of the SIG and the subsequent meetings of the SLE Working Group was to
-
Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-14 Elana J. Bernstein, Christopher P. Denton, Suiyuan Huang, Dinesh Khanna
Objective Interstitial lung disease (ILD) is the leading cause of death in adults with systemic sclerosis (SSc). The identification of biomarkers to predict progression of SSc-ILD is an important unmet need. The purpose of this study was to determine whether an elevated baseline absolute monocyte count (AMC) is associated with a decline in forced vital capacity (FVC) at 48 weeks among participants
-
Effects of exercise-based interventions on inflammatory markers in patients with fibromyalgia: A systematic review and meta-analysis Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-13 Luis Suso-Martí, Rodrigo Núñez-Cortés, Alberto Sánchez-Sabater, Miriam Garrigós-Pedrón, Francisco José Ferrer-Sargues, Rubén López-Bueno, Joaquín Calatayud
Objectives The aim of the present review was (1) to determine the effects of exercise based-interventions (EBIs) on pro-inflammatory and anti-inflammatory biomarkers in patients with fibromyalgia (FM), and (2) to determine the most effective type (acute or maintained) and modality (aerobic, resistance, etc.). Methods A systematic search was conducted in various electronic databases to identify all
-
KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-13 Cristiana Sieiro Santos, Sara Calleja Antolín, Javier De la Calle Lorenzo, Carmen López Garay, Clara Moriano Morales, Elena Bollo de Miguel, Miriam Retuerto Guerrero, Laura Sierra Herránz, Elvira Díez Álvarez
Background Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Serum biomarkers have been suggested as indicators for pulmonary damage with clinical value in the diagnosis and prognosis of SSc-ILD. Objectives To investigate the role of serum biomarkers (Krebs von den Lungen-6 KL-6, IL-18 and IL-18BP) as a potential biomarker reflecting
-
Janus kinase inhibitor and the risk of venous thromboembolism in rheumatoid arthritis patients—A global federated health network analysis Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-12 Shuo-Yan Gau, Hui-Chin Chang
Abstract not available
-
Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-12 Young-Eun Kim, Ye-Jee Kim, Dae Hyun Jeong, Seonok Kim, Min Jee Kim, Hyeon Hwa Kim, Kyung-Wook Jo, Sang Hyoung Park, Seokchan Hong
-
SAPHO syndrome: Patient stratification and the new horizon of precision medicine Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-12 Caterina Matucci-Cerinic, Gianmaria Viglizzo, Marco Gattorno
Abstract not available
-
A population-based analysis of rheumatology care patterns for inflammatory arthritis during COVID-19 in Alberta, Canada Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-11 Claire E.H. Barber, Brendan Cord Lethebe, Jessie Hart Szostakiwskyj, Cheryl Barnabe, Megan R.W. Barber, Steven Katz, Bryant R. England, Glen S. Hazlewood
Objective The aim of the study was to understand the impact of the COVID-19 pandemic on inflammatory arthritis (IA) rheumatology care in Alberta, Canada. Methods We used linked provincial health administrative datasets to establish an incident cohort of individuals with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and Ankylosing Spondylitis (AS) seen at least once by a rheumatologist. We examined
-
Generating a list of potentially important contextual factors covering randomized trials, cohorts, and measurement property studies: An OMERACT initiative Semin. Arthritis Rheum. (IF 5.0) Pub Date : 2024-01-10 Max Weinbrecht-Mischkewitz, Midhat Kamal, Farwa Asim, Francis Guillemin, Niti Goel, Marieke Voshaar, Annelies Boonen, Dorthe Bang Berthelsen, Karine Toupin-April, Maria A. Lopez-Olivo, Victor S. Sloan, Maarten Boers, C. Allyson Jones, Irene van der Horst-Bruinsma, Aidan G. Cashin, Saurab Sharma, Amye Leong, Rieke Alten, Beverley Shea, Lyn March, Sabrina Mai Nielsen
Objectives To generate candidates for contextual factors (CFs) for each CF type (i.e., Effect Modifying Contextual Factors (EM-CFs), Outcome Influencing Contextual Factors (OI-CFs), and Measurement Affecting Contextual Factors (MA-CFs)) considered important within rheumatology. Methods We surveyed OMERACT working groups and conducted a Special Interest Group (SIG) session at the OMERACT 2023 meeting